Stock solutions of Resiquimod in DMSO or ethanol may be stored at -20°C for a maximum duration of 2 months.
SML0196
Resiquimod
≥98% (HPLC), powder, TLR7/TLR8 agonist
Synonym(s):
4-Amino-2-(ethoxymethyl)-alpha, R-848, R848, S28463, alpha-dimethyl-1H-imidazo(4,5-c)quinoline-1-ethanol
Sign Into View Organizational & Contract Pricing
Select a Size
10 MG
€120.00
50 MG
€503.00
All Photos(3)
Select a Size
Change View
10 MG
€120.00
50 MG
€503.00
About This Item
Empirical Formula (Hill Notation):
C17H22N4O2
CAS Number:
Molecular Weight:
314.38
MDL number:
UNSPSC Code:
51111800
PubChem Substance ID:
NACRES:
NA.77
Recommended Products
Product Name
Resiquimod, ≥98% (HPLC)
Quality Level
Assay
≥98% (HPLC)
form
powder
storage condition
desiccated
protect from light
color
white to tan
solubility
DMSO: 10 mg/mL, clear (warmed to 60 °C)
shipped in
wet ice
storage temp.
−20°C
SMILES string
CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O
InChI
1S/C17H22N4O2/c1-4-23-9-13-20-14-15(21(13)10-17(2,3)22)11-7-5-6-8-12(11)19-16(14)18/h5-8,22H,4,9-10H2,1-3H3,(H2,18,19)
InChI key
BXNMTOQRYBFHNZ-UHFFFAOYSA-N
Application
Resiquimod has been used in the stimulation of bone marrow-derived dendritic cells (BMDCs) stimulation([1] and B cells.[2] It has also been used as a ligand for toll-like receptors (TLR7) in malignant melanoma cell line B16F10.[3][4]
Resiquimod may be used in immunological and cancer-related cell signaling studies.
Biochem/physiol Actions
Resiquimod (R-848) is a potent synthetic agonist of TLR7/TLR8 that possesses antiviral and antitumoral activities.
Resiquimod belongs to the class of imidazoquinolinamines compounds with immunomodulatory effects. Resiquimod increases the levels of cytokines such as TNF-α, IL-6 and IFN-α.[5][6]
Resiquimod is 314.4 Da molecule which elicits immune function during visceral infection with L. infantum Sp. It mediates the trafficking of granulocytes, macrophages, leukocytes and dendritic cells.[7] It is a recommended topical drug for treating skin tumors like actinic keratosis (AK) and superficial basal cell carcinoma.[8]
Resiquimod is an agonist of toll-like receptor 7 and 8 (TLR- and TLR-8).
Features and Benefits
This compound is featured on the Cytokine Receptors (Interleukin-1 Receptor/TIR Family) page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Choose from one of the most recent versions:
Certificates of Analysis (COA)
Lot/Batch Number
Don't see the Right Version?
If you require a particular version, you can look up a specific certificate by the Lot or Batch number.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Customers Also Viewed
Bridget Freyne et al.
The Journal of infectious diseases, 217(11), 1798-1808 (2018-02-08)
BCG vaccination is associated with a reduction in all-cause infant mortality in high-mortality settings. The underlying mechanisms remain uncertain, but long-term modulation of the innate immune response (trained immunity) may be involved. Whole-blood specimens, collected 7 days after randomization from
AMPK Promotes Xenophagy through Priming of Autophagic Kinases upon Detection of Bacterial Outer Membrane Vesicles
Losier TT, et al.
Cell Reports, 26(8), 2150-2165 (2019)
D H Dockrell et al.
The Journal of antimicrobial chemotherapy, 48(6), 751-755 (2001-12-06)
Augmenting the host's natural immune response to viruses by the administration of exogenous cytokines such as interferon-alpha (IFN-alpha) is a strategy increasingly employed in antiviral therapeutics. Enhancing the release of endogenous cytokines is, however, an alternative approach. The imidazoquinolinamines imiquimod
Paeonol ameliorates imiquimod-induced psoriasis-like skin lesions in BALB/c mice by inhibiting the maturation and activation of dendritic cells
Meng Y, et al.
International Journal of Molecular Medicine, 39(5), 1101-1110 (2017)
Matthew S Block et al.
Melanoma research, 29(4), 420-427 (2018-12-07)
A vaccine that could expand melanoma-specific T cells might reduce the risk of recurrence of resected melanoma and could provide an alternative or adjunct to standard immunotherapy options. We tested the safety and immunogenicity of a vaccine coupling a melanoma-associated
Articles
Bioactive small molecules for immune system signaling target identification/validation and antibiotics, antivirals, and antifungals offered.
-
What are the recommended storage conditions for stock solutions of Resiquimod (item SML0196)?
1 answer-
Helpful?
-
Active Filters
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service
